Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes
暂无分享,去创建一个
Ryan L. Collins | Beryl B. Cummings | Kristen M. Laricchia | Irina M. Armean | E. Banks | K. Cibulskis | S. Gabriel | M. Daly | D. MacArthur | B. Neale | K. Karczewski | Jeff Gentry | M. Lek | E. Minikel | S. Ferriera | Z. Zappala | K. Samocha | A. O’Donnell-Luria | J. Ware | B. Cummings | Daniel P Birnbaum | J. Kosmicki | E. Pierce-Hoffman | L. Gauthier | N. Gupta | Valentín Ruano-Rubio | G. Tiao | B. Weisburd | S. Donnelly | L. Francioli | R. Collins | H. Brand | M. Talkowski | A. Ganna | David Roazen | K. Connolly | R. Walters | Jessica Alföldi | Qingbo S. Wang | K. Laricchia | M. Solomonson | N. Watts | Daniel Rhodes | M. Singer-Berk | E. Seaby | K. Tashman | Y. Farjoun | T. Poterba | Arcturus Wang | C. Seed | N. Whiffin | J. Chong | C. Vittal | Louis Bergelson | Miguel Covarrubias | Thibault Jeandet | D. Kaplan | Christopher Llanwarne | Ruchi Munshi | Sam Novod | Nikelle Petrillo | A. Saltzman | M. Schleicher | J. Soto | Kathleen M. Tibbetts | C. Tolonen | Gordon Wade | Jessica X. Chong | José Soto | D. Kaplan | Zachary Zappala | Eleanor G. Seaby
[1] A. Sands,et al. Knockouts model the 100 best-selling drugs—will they model the next 100? , 2003, Nature Reviews Drug Discovery.
[2] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[3] E. Perez-stable,et al. Division of General Internal Medicine , 2009 .
[4] Avner Schlessinger,et al. ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI , 2012 .
[5] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[6] Joseph K. Pickrell,et al. A Systematic Survey of Loss-of-Function Variants in Human Protein-Coding Genes , 2012, Science.
[7] Evan T. Geller,et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders , 2012, Nature.
[8] D. Goldstein,et al. Genic Intolerance to Functional Variation and the Interpretation of Personal Genomes , 2013, PLoS genetics.
[9] Stephan J Sanders,et al. A framework for the interpretation of de novo mutation in human disease , 2014, Nature Genetics.
[10] Korbinian Schneeberger,et al. Using next-generation sequencing to isolate mutant genes from forward genetic screens , 2014, Nature Reviews Genetics.
[11] E. Banks,et al. De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.
[12] J. Zook,et al. Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls , 2013, Nature Biotechnology.
[13] J. E. Richardson,et al. MouseMine: a new data warehouse for MGI , 2015, Mammalian Genome.
[14] Karynne E. Patterson,et al. The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. , 2015, American journal of human genetics.
[15] Ayal B. Gussow,et al. The Intolerance of Regulatory Sequence to Genetic Variation Predicts Gene Dosage Sensitivity , 2015, PLoS genetics.
[16] A. Clark,et al. Estimating the mutation load in human genomes , 2015, Nature Reviews Genetics.
[17] Judith A. Blake,et al. The Mouse Genome Database (MGD): facilitating mouse as a model for human biology and disease , 2014, Nucleic Acids Res..
[18] S. Gravel. When Is Selection Effective? , 2014, Genetics.
[19] Patrick F. Sullivan,et al. Ultra-rare disruptive and damaging mutations influence educational attainment in the general population , 2016, Nature Neuroscience.
[20] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[21] Giulio Genovese,et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia , 2016, Nature Neuroscience.
[22] Nicola J. Rinaldi,et al. Genetic effects on gene expression across human tissues , 2017, Nature.
[23] Stephan J Sanders,et al. Refining the role of de novo protein truncating variants in neurodevelopmental disorders using population reference samples , 2016, Nature Genetics.
[24] D. Durocher,et al. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens , 2017, G3: Genes, Genomes, Genetics.
[25] K. Eilbeck,et al. Settling the score: variant prioritization and Mendelian disease , 2017, Nature Reviews Genetics.
[26] Elvira Bramon,et al. The contribution of rare variants to risk of schizophrenia in individuals with and without intellectual disability , 2017, Nature Genetics.
[27] Keith Lawson,et al. Evaluation and Design of Genome-wide CRISPR/Cas9 Knockout Screens , 2017, bioRxiv.
[28] David P. Nusinow,et al. Estimating the Selective Effects of Heterozygous Protein Truncating Variants from Human Exome Data , 2017, Nature Genetics.
[29] Bryce K. Allen,et al. Comprehensive Analysis of Tissue-wide Gene Expression and Phenotype Data Reveals Tissues Affected in Rare Genetic Disorders. , 2018, Cell systems.
[30] Hannes P. Eggertsson,et al. Parental influence on human germline de novo mutations in 1,548 trios from Iceland , 2017, Nature.
[31] M. Weedon,et al. Analysis of large‐scale sequencing cohorts does not support the role of variants in UCP2 as a cause of hyperinsulinaemic hypoglycaemia , 2017, Human mutation.
[32] M. Rivas,et al. Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study , 2018, Nature Communications.
[33] Alicia R. Martin,et al. Hidden ‘risk’ in polygenic scores: clinical use today could exacerbate health disparities , 2018, bioRxiv.
[34] M. Daly,et al. ASD and ADHD have a similar burden of rare protein-truncating variants , 2018, bioRxiv.
[35] Joseph D. Janizek,et al. Accurate classification of BRCA1 variants with saturation genome editing , 2018, Nature.
[36] Leland McInnes,et al. UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..
[37] J. Pritchard,et al. Evidence for Weak Selective Constraint on Human Gene Expression , 2018, Genetics.
[38] Benjamin Neale,et al. A synthetic-diploid benchmark for accurate variant calling evaluation , 2018, Nature Methods.
[39] Alicia R. Martin,et al. Current clinical use of polygenic scores will risk exacerbating health disparities , 2018 .
[40] M. Pirinen,et al. Contribution of rare and common variants to intellectual disability in a high-risk population sub-isolate of Northern Finland , 2018, bioRxiv.
[41] Caroline F. Wright,et al. De novo mutations in regulatory elements in neurodevelopmental disorders , 2018, Nature.
[42] Alicia R. Martin,et al. Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. , 2018, American journal of human genetics.
[43] Alex Diaz-Papkovich,et al. Revealing multi-scale population structure in large cohorts , 2018, bioRxiv.
[44] Mary E. Haas,et al. Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease , 2018, Nature Communications.
[45] G. Sella,et al. Measuring intolerance to mutation in human genetics , 2018, Nature Genetics.
[46] Jörg Hakenberg,et al. Predicting the clinical impact of human mutation with deep neural networks , 2018, Nature Genetics.
[47] M. Gerstein,et al. Insights into genetics, human biology and disease gleaned from family based genomic studies , 2019, Genetics in Medicine.
[48] Jonathan M. Mudge,et al. Transcript expression-aware annotation improves rare variant discovery and interpretation , 2019, bioRxiv.
[49] D. Stainier,et al. Genetic compensation triggered by mutant mRNA degradation , 2019, Nature.
[50] Beryl B. Cummings,et al. Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson’s disease , 2019, bioRxiv.
[51] Beryl B. Cummings,et al. Evaluating potential drug targets through human loss-of-function genetic variation , 2019, bioRxiv.
[52] P. Hainaut,et al. Variable population prevalence estimates of germline TP53 variants: A gnomAD‐based analysis , 2018, Human mutation.
[53] Grace Tiao,et al. An open resource of structural variation for medical and population genetics , 2019 .
[54] D. Mathews,et al. CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation , 2019, Nature Communications.
[55] Beryl B. Cummings,et al. Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes , 2019, bioRxiv.
[56] Tariq Ahmad,et al. Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 individuals , 2019, bioRxiv.
[57] Michael J Bamshad,et al. Mendelian Gene Discovery: Fast and Furious with No End in Sight. , 2019, American journal of human genetics.
[58] M. Hall. National Heart, Lung, and Blood Institute , 2020, The Grants Register 2022.